18:58 , Aug 31, 2018 |  BC Week In Review  |  Company News

Dermavant, NovaQuest in milestone deal for tapinarof

The Dermavant Sciences dermatology subsidiary of Roivant Sciences GmbH (Basel, Switzerland) received the $100 million investment from NovaQuest Capital Management in exchange for milestone payments related to tapinarof. The aryl hydrocarbon receptor (AHR) modulator has...
20:44 , Aug 28, 2018 |  BC Extra  |  Company News

Roivant units Urovant, Dermavant in deals as NEA’s Torti joins ‘vant’ team

Two Roivant Sciences GmbH (Basel, Switzerland) subsidiaries struck deals on Tuesday, with Urovant Sciences gaining rights to a gene therapy for overactive bladder and Dermavant Sciences receiving a $100 million investment tied to its tapinarof. The...
23:46 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Metabolic syndrome Patient sample and mouse studies suggest AHR agonists could help treat metabolic syndrome. In patient fecal samples, levels of endogenous AHR ligands -- including indole, indole acetic acid, 3-methylindole and tryptamine --...
23:54 , Apr 26, 2018 |  BC Innovations  |  Targets & Mechanisms

Raising metabolism

In the wake of the failure of ECHO-301, drug developers are asking whether the trial design or the target is at fault. But while the value of IDO1 as a target is still in doubt,...
16:58 , Mar 16, 2018 |  BC Week In Review  |  Financial News

Synthetic lethality company Ideaya raises $94M

Ideaya Biosciences Inc. (South San Francisco, Calif.) raised $94 million in a series B round on March 15 led by Nextech Invest, 6 Dimensions Capital, BVF Partners and Perceptive Advisors. Fellow new investors GV, Roche...
00:20 , Mar 16, 2018 |  BioCentury  |  Finance

Following its blueprint

Ideaya Biosciences Inc.’s goal of developing treatments for genomically defined subsets of cancer patients led Nextech Invest to co-lead the company’s $94 million series B round. Nextech, 6 Dimensions Capital, BVF Partners and Perceptive Advisors led...
11:55 , Mar 15, 2018 |  BC Extra  |  Financial News

Synthetic lethality company Ideaya raises $94M

Ideaya Biosciences Inc. (South San Francisco, Calif.) raised $94 million in a series B round led by Nextech Invest, 6 Dimensions Capital, BVF Partners and Perceptive Advisors. Fellow new investors GV, Roche Venture Fund, Boxer...
21:28 , Dec 15, 2017 |  BioCentury  |  Finance

Kyndred spirits

Partners Kyn Therapeutics Inc. and Arrys Therapeutics Inc. share an investor syndicate and a focus on cancer therapies targeting metabolic pathways in immune cells. However, the companies are keeping their assets separate to keep the...
20:51 , Dec 15, 2017 |  BC Week In Review  |  Financial News

Kyn, Arrys raise series A rounds from Atlas, Orbimed

On Dec. 14, immuno-oncology companies Kyn Therapeutics Inc. (Cambridge, Mass.) and Arrys Therapeutics Inc. (Cambridge, Mass.) announced a collective $49 million in series A funding from Atlas Venture and OrbiMed Advisors. Arrys raised $21 million, while...
20:49 , Dec 14, 2017 |  BC Innovations  |  Translation in Brief

STUBbing out thrombosis

Patients with chronic kidney disease are at a higher risk of thrombosis, especially following surgery and dialysis, but are also at a higher risk of bleeding than healthy individuals, making standard antithrombotic therapies dangerous. A...